NCT00190697已完成4 期
Continuation of Treatment and Monitoring of Safety in Patients Treated With LY353381 for Advanced Cancer
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 70
- 试验地点
- 2
- 主要终点
- To allow continued treatment of patients who exhibited clinical benefit from arzoxifene
研究概览
简要总结
Patients who were previously enrolled on the LY353381 arm of any LY353381 oncology trial could enroll in this "roll-over" study if they had exhibited clinical benefit from treatment and wished to continue on treatment. Patients were monitored for safety.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Participation in a clinical trial of LY353381 that has met its main safety and efficacy objectives, and could otherwise close.
- •Evidence of continuing benefit with LY353381 (eg. complete response, partial response or stable disease with no symptomatic or clinical evidence of disease progression).
- •Adequate bone marrow reserve, liver and renal function, consistent with the previous LY353381 protocol, with no recent significant deterioration or metabolic condition that could affect patient safety or compliance with the protocol (eg, hypercalcemia).
- •Written informed consent from patient.
- •Childbearing potential either terminated by surgery, radiation, menopause, or attenuated by use of an intra-uterine contraceptive device or barrier method during and for 3 months after the trial.
排除标准
- •No concurrent systemic therapy (immunotherapy, hormone therapy or chemotherapy) for cancer. Palliative radiotherapy is allowed (eg, for pain) as long as there is no evidence of disease progression. Investigational agents, other than LY353381, within the 4 weeks prior to this study enrollment and other SERMs are also not permitted.
- •No concurrent use of oral contraceptives, GnRH agonists, or coumarin (warfarin).
- •No serious concomitant systemic disorders incompatible with the study (at the discretion of investigator), including predisposition to thromboembolic disorder.
- •Must not be pregnant or breast-feeding.
- •Must not have a gap in treatment of more than 4 weeks between previous LY353381 study and enrollment in current study.
结局指标
主要结局
To allow continued treatment of patients who exhibited clinical benefit from arzoxifene
次要结局
- To collect long-term safety data on arzoxifene use in advanced cancer patients
研究者
研究点 (2)
Loading locations...
相似试验
Available
不适用
Master Rollover Protocol for Continued Safety Assessment of Study DrugCancerNCT02632994Eli Lilly and Company
已完成
不适用
A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.NeoplasmsNCT00443534Pfizer123
已完成
1 期
ATRi Transition Rollover StudyAdvanced Stage Solid TumorsNCT03309150Merck KGaA, Darmstadt, Germany1
终止
1 期
A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511Gliomas, MalignantGlioblastoma MultiformeAstrocytomaNCT04327011Tocagen Inc.65
已完成
3 期
Extension Study: Evaluating the Safety of Oral Ziprasidone in the Treatment of Subjects With SchizophreniaSchizophreniaNCT00139737Pfizer's Upjohn has merged with Mylan to form Viatris Inc.344